1. Home
  2. GCTK vs JAGX Comparison

GCTK vs JAGX Comparison

Compare GCTK & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCTK

GlucoTrack Inc.

HOLD

Current Price

$0.30

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.98

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTK
JAGX
Founded
2001
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.2M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
GCTK
JAGX
Price
$0.30
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
1.6M
66.1K
Earning Date
05-13-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
2.65
N/A
Revenue
$589,462.00
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
$0.12
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.22
52 Week High
$14.14
$8.00

Technical Indicators

Market Signals
Indicator
GCTK
JAGX
Relative Strength Index (RSI) 34.37 22.36
Support Level N/A $0.60
Resistance Level $0.63 $0.99
Average True Range (ATR) 0.07 0.24
MACD -0.01 -0.13
Stochastic Oscillator 0.03 0.00

Price Performance

Historical Comparison
GCTK
JAGX

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: